TOI Oncology Institute Inc
Price (delayed)
$1.48
Market cap
$112.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$53,005
Enterprise value
$185.6M
Highlights
The EPS has grown by 22% YoY and by 22% from the previous quarter
Oncology Institute's net income has increased by 22% YoY and by 8% QoQ
TOI's equity has dropped by 94% year-on-year and by 77% since the previous quarter
The quick ratio has contracted by 48% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of TOI
Market
Valuations
Earnings
Shares outstanding
75.75M
Market cap
$112.11M
Enterprise value
$185.6M
Price to earnings (P/E)
N/A
Price to book (P/B)
31.16
Price to sales (P/S)
0.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.47
Revenue
$393.41M
Gross profit
$54M
Operating income
-$60.12M
Net income
-$64.66M
EBIT
-$57.17M
EBITDA
-$50.88M
Free cash flow
-$30.33M
Per share
Balance sheet
Liquidity
EPS
-$53,005
EPS diluted
-$53,005
Free cash flow per share
-$0.4
Book value per share
$0.05
Revenue per share
$5.24
TBVPS
$2.01
Total assets
$172.72M
Total liabilities
$169.13M
Debt
$123.15M
Equity
$3.59M
Working capital
$60.2M
Debt to equity
34.31
Current ratio
2.15
Quick ratio
1.88
Net debt/EBITDA
-1.44
Margins
Efficiency
Dividend
EBITDA margin
-12.9%
Gross margin
13.7%
Net margin
-16.4%
Operating margin
-15.3%
Return on assets
-35.1%
Return on equity
-288.8%
Return on invested capital
-29.3%
Return on capital employed
-47.4%
Return on sales
-14.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TOI stock price
How has the Oncology Institute stock price performed over time
Intraday
17.46%
1 week
22.31%
1 month
73.69%
1 year
-3.9%
YTD
378.96%
QTD
29.82%
Financial performance
How have Oncology Institute's revenue and profit performed over time
Revenue
$393.41M
Gross profit
$54M
Operating income
-$60.12M
Net income
-$64.66M
Gross margin
13.7%
Net margin
-16.4%
The company's net margin rose by 36% YoY and by 11% QoQ
Oncology Institute's operating margin has increased by 36% YoY and by 9% from the previous quarter
The gross margin has contracted by 26% YoY and by 3.5% from the previous quarter
Oncology Institute's net income has increased by 22% YoY and by 8% QoQ
Growth
What is Oncology Institute's growth rate over time
Valuation
What is Oncology Institute stock price valuation
P/E
N/A
P/B
31.16
P/S
0.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.47
The EPS has grown by 22% YoY and by 22% from the previous quarter
The stock's P/B is 160% more than its 5-year quarterly average of 10.2
TOI's equity has dropped by 94% year-on-year and by 77% since the previous quarter
The P/S is 140% more than the last 4 quarters average of 0.1 but 83% less than the 5-year quarterly average of 1.4
TOI's revenue is up by 21% year-on-year and by 3.8% since the previous quarter
Efficiency
How efficient is Oncology Institute business performance
The company's return on equity has shrunk by 171% YoY and by 47% QoQ
The ROS has grown by 38% YoY and by 12% from the previous quarter
The ROA is up by 6% year-on-year and by 3.6% since the previous quarter
The company's return on invested capital rose by 2% YoY
Dividends
What is TOI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TOI.
Financial health
How did Oncology Institute financials performed over time
The total assets is 2.1% more than the total liabilities
The current ratio has contracted by 48% YoY and by 14% from the previous quarter
The quick ratio has contracted by 48% YoY and by 14% from the previous quarter
TOI's equity has dropped by 94% year-on-year and by 77% since the previous quarter
The company's debt rose by 2.9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.